NISOLDIPINE

Post-LOESM

nisoldipine

R-Pharm US

ANDAORALTABLET, EXTENDED RELEASE

Approved

Apr 2023

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

5/8 — Partial

NISOLDIPINE (nisoldipine) by R-Pharm US is mechanism of action nisoldipine is a member of the dihydropyridine class of calcium channel antagonists (calcium ion antagonists or slow channel blockers) that inhibit the transmembrane influx of calcium into vascular smooth muscle and cardiac muscle. Approved for hypertension. First approved in 2023.

Drug data last refreshed 20h ago

$0.0BPart D

Mechanism of Action

Mechanism of Action Nisoldipine is a member of the dihydropyridine class of calcium channel antagonists (calcium ion antagonists or slow channel blockers) that inhibit the transmembrane influx of calcium into vascular smooth muscle and cardiac muscle. It reversibly competes with other…

Indications (1)

hypertension

Worked on NISOLDIPINE at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

NISOLDIPINE

Mechanism of Action

Indications (1)

Clinical Trials (1)